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Abstract: The melanocortin 4 receptor (MC4R) is a key player in hypothalamic weight regulation and
energy expenditure as part of the leptin–melanocortin pathway. Mutations in this G protein coupled
receptor (GPCR) are the most common cause for monogenetic obesity, which appears to be mediated
by changes in the anorectic action of MC4R via GS-dependent cyclic adenosine-monophosphate
(cAMP) signaling as well as other signaling pathways. To study potential bias in the effects of MC4R
mutations between the different signaling pathways, we investigated three major MC4R mutations: a
GS loss-of-function (S127L) and a GS gain-of-function mutant (H158R), as well as the most common
European single nucleotide polymorphism (V103I). We tested signaling of all four major G protein
families plus extracellular regulated kinase (ERK) phosphorylation and β-arrestin2 recruitment,
using the two endogenous agonists, α- and β-melanocyte stimulating hormone (MSH), along with
a synthetic peptide agonist (NDP-α-MSH). The S127L mutation led to a full loss-of-function in all
investigated pathways, whereas V103I and H158R were clearly biased towards the Gq/11 pathway
when challenged with the endogenous ligands. These results show that MC4R mutations can cause
vastly different changes in the various MC4R signaling pathways and highlight the importance of a
comprehensive characterization of receptor mutations.
Keywords: Melanocortin 4 receptor (MC4R); Melanocyte stimulating hormones MSH; G protein
coupled receptor (GPCR); biased signaling
1. Introduction
A complex hypothalamic network of orexigenic and anorexigenic signals regulates body weight
and energy expenditure. One of the key players in this network is a G protein coupled receptor (GPCR),
the melanocortin 4 receptor (MC4R), which is mainly expressed in the paraventricular nucleus (PVN)
of the hypothalamus. The MC4R receives input from the leptin–melanocortin pathway and thereby
integrates peripheral and central metabolic signals. Activation of the MC4R by the proopiomelanocortin
(POMC)-derived melanocyte stimulation hormones alpha and beta (α-MSH, β-MSH) counteracts the
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signal of orexigenic peptides such as neuropeptide Y (NPY), Agouti-related peptide (AgRP) or ghrelin,
and therefore deceases appetite [1–3]. Its pivotal role in weight homeostasis became obvious when
mutations in the MC4R gene were identified in obese patients [4,5].
The MC4R signals mainly via activation of the stimulating G protein GS, which leads to an
increase in intracellular cyclic adenosine-monophosphate (cAMP) [6]. In recent years, more and more
studies provided evidence that the MC4R is able to couple to a variety of signaling pathways, such
as extracellular regulated kinase (ERK) activation [7–9], and to other G proteins, such as Gi/o, Gq/11
and G12/13 [10–13]. These pathways might also be involved in the anorexigenic effect of the activated
MC4R [14]. The receptor exhibits ligand-independent constitutive activity (basal activity) [15] and is
able to form homodimers as well as homo-oligomers [16]. The endogenous peptide AgRP has been
described to reduce this constitutive activity, i.e., to act as an inverse agonist [15,17] or as a competitive
antagonist [15,18]. In addition to MC4R activation by endogenous ligands, the MC4R can be activated
by a variety of synthetic peptide ligands, such as (Nle4, d-Phe7)-α-MSH (NDP-α-MSH) [19].
So far, many mutations identified in obese patients have been functionally characterized in
overexpressing in vitro systems, and a number of these mutations showed a loss-of-function in GS
signaling. However, other MC4R mutations were described as wild type (WT)-like and were, therefore,
believed to be irrelevant for the obese patient phenotype.
In recent years, several MC4R mutations have been identified that exhibit biased signaling, which
is defined as the selective activation or inactivation of one pathway over another [20]. Tao and
colleagues were the first to describe biased signaling of MC4R mutations in the mitogen-activated
protein kinase (MAPK) pathway. Interestingly, in some of the tested mutations no functional defect
in GS signaling had been described before [21]. Recently, bias towards β-arrestin has been studied,
revealing mutations with unremarkable changes in GS signaling but with a markedly affected ability
to recruit β-arrestins [22,23].
These observations indicate that it may be necessary to study more than just the receptor’s
GS-signaling properties in order to fully characterize MC4R mutations. The aim of the current study
was, therefore, the comprehensive characterization of three prototypical MC4R mutations in their
ability to activate all four major G protein families, plus ERK activation, β-arrestin2 recruitment and
ligand-dependent internalization. As a proof of principle study, we focused on a very common MC4R
variant, V103I, and two MC4R missense mutations: S127L and H158R.
The most common single nucleotide polymorphism (SNP) in Europe, V103I, is located in the
transmembrane domain (TMD) 2, and has been mostly described as WT-like in GS signaling [24–29]
and has been suggested to be protective against obesity [23,30–37]. The second MC4R mutation, S127L,
has been frequently reported as a partial loss-of-function in GS signaling, which has an increased
constitutive activity and is located in TMD 3 [26,38–45]. The third investigated naturally occurring
MC4R mutation, H158R, is a constitutively active gain-of-function mutation in GS signaling that has
a decreased ability to form homodimers [46,47]. It is located in the second intracellular loop (ICL2).
Since V103I is the only MC4R variant, which is defined by a minor allele frequency (MAF) above one
percent in the normal population, whereas the other two are considered to be rare with a lower MAF,
we will continue referring to all of them with the term “mutations”.
With regard to the GS activation pattern, these three mutations are vastly different. However, these
findings do not strictly align with the phenotype. This suggests that other GPCR signaling pathways
might be important for weight regulation, and therefore these were investigated in the present study.
2. Results
In this study, we characterize the three described MC4R mutations in vitro for all known/so far
reported signaling pathways to explore the role of GS and non-GS pathways in weight regulation.
Therefore, in addition to cAMP measurements to assess GS activation in the absence and presence of
100 nM AgRP, we measured Gi/o activation via determination of second messenger (cAMP) modulation
by adenylyl cyclase (AC) in the absence or presence of pertussis toxin (PTX) pretreatment. In the
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presence of PTX, which locks the Gαi/o subunit in its GDP-bound inactivated state, the G protein is
no longer able to inhibit the AC to form cAMP [48]. Although this is an indirect way of measuring
the contributions from Gi/o signaling to the total amount of intracellular cAMP, we will refer to these
measurements as Gi/o coupling in order to simplify the results part. We used reporter gene assays
measuring phospholipase C (PLC) activity through nuclear factor of activated T-cell (NFAT) response
for Gq/11, RhoA activation via serum-response factor (SRF) for G12/13, and ERK1/2 phosphorylation via
the serum response element (SRE). Recruitment of β-arrestin2 by the receptor after the ligand challenge
was determined by protein interaction studies and total and cell surface expression were analyzed
using a protein complementation assay. In addition, ligand-induced internalization was visualized by
staining the receptor with a fluorophore-coupled ligand.
2.1. Total and Cell Surface Expression of the Three MC4R Mutations
Cell surface and total expression of all three variants were determined. This provides information
on protein folding and how the mutation influences the trafficking of the receptor to the plasma
membrane, which may influence signaling. Introduction of these three mutations into the MC4R did
not result in any significant changes in cell surface expression and total expression (Figure 1).
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Figure 1. Cell surface expression and total expression of the melanocortin 4 receptor (MC4R) 
mutations do not significantly differ from each other. HEK293 cells were transfected with N-
terminally HiBiT-tagged MC4R, a small protein tag, which is able to complement a split luciferase 
that cannot cross the plasma membrane. Either the cells membrane remained intact to determine 
receptors at the cell surface, or cells were lysed to determine the total expression of MC4R mutations. 
(a) Expression on the cell surface did not differ between the three MC4R mutations. (b) The total cell 
expression of the MC4R mutations was also not different. Values represent mean ± SEM from three 
to four independent experiments performed in triplicates. Statistical analysis was performed using a 
one-way ANOVA, followed by Dunnett’s post-hoc test. 
2.2. Internalization of the Three MC4R Mutations 
In order to investigate the internalization ability of all three MC4R mutations, we used confocal 
imaging of labeled MC4R as well as β-arrestin2 recruitment as an indication of receptor 
desensitization. In our experience, MC4R C-terminally tagged with GFP is exhibiting signaling 
deficits, hence we chose another labeling approach. We used TAMRA-labeled NDP-α-MSH in order 
to stain receptors expressed at the cell surface and quantified the amount of labeled receptors in 
endosomes after 30 min of stimulation using confocal images (Figure 2). When compared with MC4R 
WT, we observed less endosomes containing V103I, whereas S127L and H158R showed an increased 
internalization (Table S1). It should be noted that when the amount of DNA transfected and the image 
contrast were held stable for all confocal images, V103I showed stronger staining compared to the 
WT. This suggests that the internalization deficit of this mutation increases the amount of receptors 
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tati s do not significantly differ from each other. HEK293 cells were transfected with N-terminally
HiBiT-tagged MC4R, a small protein tag, which is able to complement a s lit luciferase that cannot
cross the plasma membrane. Either the cells membrane remained intact to determine receptors at the
cell surface, or cells were lysed to determine the total expression of MC4R mutations. (a) Expression on
the cell surface did not differ between the three MC4R mutations. (b) The total cell expression of the
MC4R mutations was also not different. Values represent mean ± SEM from three to four independent
experiments performed in triplicates. Statistical analysis was performed using a one-way ANOVA,
followed by Dunnett’s post-hoc test.
2.2. Internalization of the Three MC4R Mutations
In order to investigate the internalization ability of all three MC4R mutations, we used confocal
imaging of labeled MC4R as well as β-arrestin2 recruitment as an indication of receptor desensitization.
In our experience, MC4R C-terminally tagged with GFP is exhibiting signaling deficits, hence we
chose another labeling approach. We used TAMRA-labeled NDP-α-MSH in order to stain receptors
expressed at the cell surface and quantified the amount of labeled receptors in endosomes after 30 min
of stimulation using confocal images (Figure 2). When compared with MC4R WT, we observed less
endosomes containing V103I, whereas S127L and H158R showed an increased internalization (Table S1).
It should be noted that when the amount of DNA transfected and the image contrast were held stable
for all confocal images, V103I showed stronger staining compared to the WT. This suggests that the
internalization deficit of this mutation increases the amount of receptors on the cell surface after
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stimulation, although the cell surface expression of the mutation was not significantly increased in the
absence of a ligand, as shown in Figure 1.
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the MC4R WT.
2.3. Comprehensive Functional Characterization of the Three MC4R Mutations
A complete characterization of all known pathways for three receptor mutations for three different
agonists generates a substantial amount of data (Figure 1, Figures S1 and S2, and Tables S2–S4).
The intention of this study was the evaluation of three mutations in comparison to WT signaling
(determination of biased signaling) after a challenge with the two endogenous ligands and a highly
potent (in GS signaling) peptidic ligand. Therefore, an easy way to communicate biased signaling was
used to present the results in a more comprehensive way, by plotting the bias calculated as described
in the method section for each MC4R mutation. The values derived from concentration–response
experiments (all concentration–response curves for all mutations and the three ligands are presented
in Figure 3), which were fitted to non-linear regression models to calculate the efficacy of each ligand
at the receptor mutation (Emax) and the potency of the ligand at the receptor mutation (EC50). Values
were normalized to the reference, MC4R WT, which is plotted as 1.0 for each pathway. Values above 1.0
represent an increase in signaling capacity in this pathway in comparison to the WT, whereas values
below 1.0 represent a decrease in activity. Mutations with a WT-like behavior have bias values close to
1.0, meaning that there is in fact no bias. Efficacy, potency and bias values are stated in supplemental
Tables S2–S4.
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2.3.1. Stimulation with α-MSH Leads to a Strong Signaling Bias towards the Gq/11 Pathway for MC4R
Mutations V103I and H158R
Functional characterizations of MC4R mutations are usually performed with the endogenous
agonist α-MSH in most published studies. We characterized MC4R mutations V103I, S127L and
H158R in all mentioned pathways with this ligand and identified that all three mutations showed clear
signaling biases towards particular pathways (Figure 4).
The mutation V103I exhibited a strong bias towards PLC activation via Gq/11, where it clearly
showed a gain-of-function. On the other hand, it had a decreased capacity to couple to Gi/o. The data
suggest a tendency towards a reduced antagonist effect of AgRP, which was, however, not significant.
In every other tested pathway, the mutation signal was comparable to the WT after stimulation with
α-MSH. This is in line with most published data regarding this mutation [24–26].
The loss-of-function mutant S127L was clearly impaired in every tested pathway when challenged
with α-MSH. Treatment with AgRP showed a trend towards reduced antagonistic potency, which was
again not significant.
We found the already-reported gain-of-function in GS signaling for the H158R mutation with a
decreased EC50 and an increase in maximal response (Emax) [46]. Interestingly, the increase in bias
values for GS signaling in the presence of AgRP implies a loss-of-antagonist effect for the mutation.
Notably, H158R showed a similar strong bias towards Gq/11 as the V103I mutant with a rise in PLC
activation. In other tested pathways, the mutation closely resembled the WT activity.
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Figure 4. MC4R mutations V103I and H158R have a strong bias towards NFAT via PLC activation
after challenge with α-MSH. As a reference, MC4R WT (gray) is plotted at a value of 1.0. The V103I
mutant (blue) acted similarly to the WT in most pathways tested but had increased activity in the Gq/11
pathway, and a decrease in Gi/o coupling. MC4R S127L (green) lost function in all tested pathways but
responded to the antagonist Agouti related peptide (AgRP) in a similar manner to the WT. H158R (red)
was a gain-of-function mutation for both the GS and Gq/11 pathway. Each value is based on EC50 and
Emax values that were derived from non-linear regression models fitted to the concentration–response
curves for each pathway from three to seven independent experiments performed in triplicates.
2.3.2. Challenge with β-MSH Results in a Different Activation Pattern Compared to α-MSH for MC4R
V103I and H158R Mutations
The second endogenous agonist for MC4R, β- SH has been neglected in most MC4R studies so
far, but is proven to be important for weight reg l ti [22,48,49] and was therefore included in this
study (Figure 5).
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shows a signaling behavior that is very close to MC4R WT when stimulated with NDP-α-MSH. This 
potent agonist was not able to rescue the loss-of-function mutation S127L and its diminished 
signaling capacity remained, except for β-arrestin2 recruitment that exhibited a WT-like behavior. 
Lastly, MC4R H158R showed the typical gain-of-function in GS signaling when challenged with NDP-
α-MSH. Strikingly, this mutation also lost the strong bias towards PLC activation via Gq/11, but 
exhibits clear bias towards G12/13 and ERK phosphorylation with increased signaling. 
Figure 5. A β-MSH challenge c different responses for MC4R mutations V103I and H158R.
As ref r nce, MC4R WT (gra at a value of 1.0. The V103I mutation (blue) showed impaired
signaling activity in the GS pathway with and ithout gRP, but had a strong bias towards Gq/11
(NFAT) and G12/13 (SRF), as well as towards Gi/o signaling. MC4R S127L (green) was impaired in all
tested pathways. H158R (red) is a gain-of-function mutation for the GS, Gi/o and Gq/11 pathway, as well
as for ERK phosphorylation. Each value is based on EC50 and Emax values that were derived from
non-linear regression models fitted to the concentration–response curves for each pathway from three
to seven independent experiments performed in triplicates.
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Here, the V103I mutation presents itself with a distinctly different signaling behavior compared to
α-MSH stimulation. Although it still exhibits an increased Gq/11 coupling, its capacity to activate the GS
pathway is reduced (though not significantly), which is also reflected in its response to the antagonist
AgRP. In addition, it showed a strong positive bias towards Gi/o coupling, RhoA activation via G12/13
and increased ERK phosphorylation. S127L on the other hand again presented full loss-of-function in
all tested pathways and even its response to AgRP was impaired. The responses of H158R to β-MSH
were comparable to its α-MSH responses with increased GS and Gq/11 signaling and WT-like activity in
G12/13 and β-arrestin2 recruitment, though it also showed augmented ERK phosphorylation. Again,
AgRP loses its antagonistic effect for this mutation. In contrast to α-MSH, H158R showed a strong bias
towards Gi/o signaling when stimulated with β-MSH.
2.3.3. MC4R V103I and H158R Lost Their bias Towards Gq/11 After NDP-α-MSH Stimulation
NDP-α-MSH, a synthetic peptide analogue to α-MSH, is a very potent agonist [50] and its
radiolabeled versions are suitable for in vitro testing of MC4R mutations. Since it is widely used, we
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The loss-of-function mutation S127L (green) could not be rescued by NDP-α-MSH in most pathways,
but β-arrestin2 recruitment was restored to WT-like. The H158R mutant (red) kept its gain-of-function
in GS signaling as was well as in G12/13 and ERK phosphorylation, at the same time it lost the strong
bias towards Gq/11 that was displayed with the α-MSH challenge. Each value is based on EC50 and
Emax values that were derived from non-linear regression models fitted to the concentration–response
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In comparison to the endogenous ligands, the V103I mutant signaling characteristics after the
NDP-α-MSH challenge showed yet again a different picture. Most notably, the bias towards Gq/11 was
absent and PLC activation was similar to WT. In addition, GS signaling was increased in comparison to
WT activity, which was then also reflected in its response to the antagonist AgRP. RhoA activation via
G12/13 as well as ERK phosphorylation were increased, but the general picture of this mutation shows a
signaling behavior that is very close to MC4R WT when stimulated with NDP-α-MSH. This potent
agonist was not able to rescue the loss-of-function mutation S127L and its diminished signaling capacity
remained, except for β-arrestin2 recruitment that exhibited a WT-like behavior. Lastly, MC4R H158R
showed the typical gain-of-function in GS signaling when challenged with NDP-α-MSH. Strikingly,
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this mutation also lost the strong bias towards PLC activation via Gq/11, but exhibits clear bias towards
G12/13 and ERK phosphorylation with increased signaling.
3. Discussion
To understand the underlying molecular mechanisms caused by mutations in GPCRs in general, a
comprehensive functional characterization is essential. Based on the complexity of changes induced by
genetic variants a proper characterization should include evidence on the following aspects: (1) How
does a mutation influence the total receptor expression in the cell? (2) What is the impact of the
mutations on cell surface expression? (3) Is there any signaling bias involving all known signaling
pathways and endogenous ligands for this specific GPCR? (4) Does a mutation create any bias of
ligand-induced G protein activation versus β-arrestin recruitment? (5) Does an altered response to
the antagonist (in case of a known endogenous antagonist) exist? This extensive study can help to
elucidate the role of each of these mechanisms in the physiological and potential pathophysiological
role of a receptor and its mutations.
Furthermore, it will be of importance to establish benchmarks and guidelines concerning the
way in which in vitro data of the functional characterization should be presented. Here, it would be
relevant to present either raw data or calculated values normalized to WT basal activity (at equivalent
expression levels) to ensure comparability of assay data. We recommend with respect to MC4R-related
in vitro assays that EC50 should only be calculated if the maximal response is greater than 25% of the
maximal WT activity. In addition, the use of different read-out systems for signaling pathways makes
a comparison between different studies difficult, therefore a clear statement is necessary on how those
data were determined.
Additionally, the choice of cell system may affect the results and should be considered carefully.
Endogenous cell systems are always considered the best choice; however, for many studies those are
not available. Chinese hamster ovarian (CHO) and African green monkey (COS) cell lines are easy to
transfect and are able to produce high amounts of second messengers such as cAMP, which gives them
an important role in GPCR research. For neuroendocrine receptors, hypothalamic rodent cell lines, such
as GT1-7 or mHypoE-N39 and mHypoE-N41, are suitable due to their close physiological background,
but with current options, transfection has been shown to be difficult. For all the mentioned cell lines,
their non-human background complicates any actual interpretations on the physiological roles of
human receptor function. Human cell lines such as human embryonic kidney cells (HEK293) are easy
to transfect and suitable for a variety of functional assays and are well established in GPCR research.
HEK293 cells are proven to not express MCRs [51] and do not respond to NDP-α-MSH [52]. We used
this particular cell line in the presented study and are aware of the limitations of this cell system as it
does not resemble the repertoire of proteins of hypothalamic neurons. For investigations of MC4R, it
has to be noted that the melanocortin 2 receptor accessory protein 2 (MRAP2), a protein that has been
shown to decrease constitutive activity of MC4R and also increase the responsiveness to α-MSH in
GS signaling [53], is marginally expressed in our used cell system [54]. This needs to be taken into
consideration during interpretation of the data, especially regarding basal constitutive activity.
For a long time, ERK phosphorylation was considered as a G protein-independent and
β-arrestin-dependent signaling pathway. Very recently, Grundmann et al. reported data that hint
towards the need for G protein presence for ERK phosphorylation, whereas β-arrestins seem to be less
involved [55]. Therefore, we would currently consider β-arrestin2 recruitment solely as part of the
internalization machinery in the following discussion.
A recent genome-wide association study (GWAS) has reported that patients with pathogenicMC4R
mutations had a very variable outcome depending on their genetic background. Here, polygenetic
scores (PGS) were calculated for each individual, which measure the cumulative effect of common
alleles and their effects on the person’s risk of disease. So, MC4R mutations carriers with favorable
PGS had an average BMI, which was approximately equal to the population mean, while those
with an unfavorable PGS were more strongly affected [56]. Therefore, we decided not to perform
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genotype–phenotype outcome correlations, since we assume that correlation of a patient’s phenotype
with functional data would not result in robust data. In the following discussion we will focus on
the interpretation of our findings from a functional standpoint and their comparison to published
information about the tested MC4R mutations.
3.1. MC4R Mutations are Expressed Equally, but Internalize Differently
Our investigations regarding total and cell surface expression of the MC4R mutations showed
no significant change in our chosen cell system in the basal state. Therefore, we can conclude that
the results from the functional characterization reflect the actual signaling capacity of the mutations
rather than their expression on the cell surface. This is in line with published data for V103I [57] and
some reports for S127L when transfected transiently [39,40,58]. However there are conflicting results
obtained in others studies, which showed a decreased cell surface expression of S127L, but no change
in total expression in stably transfected cells [41].
In our study, the capacity to form endosomes after stimulation with NDP-α-MSH of V103I was
disturbed, which aligns with recently published data [23]. This internalization deficit might be due
to the significantly decreased β-arrestin2 recruitment we observed; however, this finding could not
be recapitulated in a recent publication [23]. This discrepancy might be explained by the way the
data is generated as we utilized a bioluminescence resonance energy transfer method (NanoBRET) in
comparison to the split-luciferase approach of the previous study (Figure 3 and Table S2). To investigate
the conflicting evidence for V103I, future approaches could involve a kinetic measurement ofβ-arrestin2
recruitment as well as phosphorylation by GPCR kinases (GRKs).
S127L has been shown to become internalized similarly to the WT when stimulated with α-MSH,
determined by ELISA studies [58]. We even found an increased amount of endosome formation after
stimulation with TAMRA-NDP-α-MSH of this mutation, which is in line with increased β-arrestin2
recruitment after stimulation with the synthetic ligand.
3.2. Constitutive Activity in all Tested Pathways Differed for Each Mutation Compared to WT-MC4R
The MC4R has been shown to be constitutively active in the GS pathway [15], and two out of
the three investigated mutations have been reported to exhibit increased basal activity. For S127L,
some publications identified a constitutive activity in GS [58,59], which could not be determined in
the present study. One reason might be that in our HEK293 cell system MRAP2 is expressed in low
amounts, which might reduce basal signaling [22,53,60]. We did, however, reproduce the increase in
basal GS coupling that was reported for H158R [46].
Since only a few studies addressed other pathways for MC4R, information about basal activity is
scarce. S127L has been investigated for ERK phosphorylation and was found to have an increased
basal activity in this pathway [57]. Although we saw a tendency towards increased constitutive ERK
activity for all tested MC4R mutations, the results were not significant. H158R, on the other hand,
was found to have reduced basal ERK phosphorylation compared to MC4R WT [21], which we could
not reproduce.
3.3. Signaling Bias towards Gq/11 of Two Mutations When Stimulated with α-MSH
The endogenous ligandα-MSH is commonly used to investigateMC4Rmutations in vitro. Its effect
has been described for all three studied mutations in various details. GS signaling determined in this
study is in accordance with the majority of already published data for all three mutations. Stimulation
by α-MSH in presence of 100 nM AgRP resulted in impaired antagonistic potency for S127L, but an
increase for H158R. For MC4R S127L, AgRP had a reduced antagonistic potency, which is in line with
published data [40]. One study suggests that V103I has a modestly reduced AgRP antagonistic potency,
though this has only been tested with a synthetic agonist (MTII) [33]. We did notice a tendency towards
a decreased antagonistic effect, which was mainly due to a low efficacy compared to the WT. For the
H158R mutation, no additional data about the potency of the antagonist exists in the literature.
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The most eminent observed effect was the increase in Gq/11 signaling for two of our mutations,
V103I and H158R, which have never been investigated in this pathway before. Over the years, evidence
has accumulated that suggests a role of PLC activation in the anorexigenic effect of MC4R, and
the activation of Gq/11 signaling through MC4R has been documented in several studies [14,61–63].
We recently reported that naturally occurring MC4R mutations are found in obese patients with normal
function in GS, but impaired NFAT activation as read-out system of Gq/11 activation could be rescued
in vitro with a synthetic ligand biased towards PLC activation [12]. This hints to the importance of the
Gq/11 pathway, as a strong bias towards PLC activation of V103I might play a part in its suggested
protective role against obesity [30–34]. The rare mutation H158R is located in the ICL2, which is part
of the G protein binding site and has been postulated to be important for Gq/11 coupling as well [64].
The observed gain-of-function in this pathway therefore suggests functional relevance of this position.
Similarly, ERK phosphorylation has been suggested to be important for MC4R function in vitro
and in vivo [7–9], though the physiological role of this pathway is poorly understood. MC4R triggered
ERK activation can be modulated by AgRP [57] and the MAPK pathway has been shown to result
from the activation of several G proteins, such as the Gi/o and Gq/11 proteins [65]. For V103I, ERK
phosphorylation has been reported to be increased after stimulation with all three tested ligands [23].
Though we see a tendency towards an ERK bias, our study did not reveal a significant increase in
activity for this pathway.
3.4. MC4R Mutations Respond Differently to the Endogenous Melanocortins
The endogenous ligands α- and β-MSH share a core amino acid sequence (His-Phe-Arg-Trp)
but differ in length and protein stability. They are both involved in the anorexigenic effect of MC4R
signaling [1,22,48,49], though the reason for two different peptides that convey a rather similar function
within the pathway is not entirely clear. For the MC4R WT there are no strong differences in the signaling
profile of the two ligands; however, GS signaling of β-MSH in the presence of 100 nM AgRP is not as
strongly affected compared to the one of α-MSH. Interestingly, the stimulation of V103I with β-MSH
had a tendency towards low GS signaling, which is conflicting with recently published results [23].
The S127L mutant again exhibited a loss-of-function in GS, as already published [40]. There is no
published information about the stimulation of H158R with β-MSH, though the gain-of-function
similar to α-MSH was expected.
For the other tested pathways, the two MC4R mutations V103I and H158R have a diverse signaling
profile when stimulated with β-MSH compared to α-MSH. They still exhibit a strong bias towards PLC,
though other signaling pathways are enhanced as well, such as Gi/o and G12/13 coupling. In addition,
H158R was able to increase ERK phosphorylation in comparison to the WT. This might be the result of
the strong bias towards Gq/11 and Gi/o coupling that increased the activation of MAPK. As mentioned
before, V103I was published to exhibit an increased ERK phosphorylation [23]. Again, in our cell
system, the mutation showed a tendency towards an ERK signaling bias, which was not significant.
3.5. The Potent Synthetic Ligand NDP-α-MSH Changes the Signaling Bias of V103I and H158R
NDP-α-MSH is an improved synthetic form of α-MSH that has been shown to be more potent
in GS signaling [19]. Again, for MC4R V103I our results in GS signaling were in line with most
publications that used NDP-α-MSH [24,66]. For S127L, conflicting results for cAMP accumulation
after NDP-α-MSH stimulation have been published with either an increase in EC50 [39,42] or a similar
EC50 compared to the WT combined with a decreased Emax [41], or both an increase in EC50 and a
diminished maximal response [40]. In our cell system, the mutation exhibited a similar signaling
profile to the endogenous ligands. The response of H158R to NDP-α-MSH was not published yet,
though again the observed gain-of-function similar to α-MSH was expected.
The synthetic ligand diminished the bias effect in the PLC of V103I and H158R, although for the
MC4R WT the synthetic agonist was more potent in all pathways investigated. Interestingly, bias
towards G12/13 and MAPK was increased for V103I. The latter has already been reported recently [23].
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Here, it cannot result from Gq/11 or Gi/o signaling, since these pathways are not increased. This hints
towards an unknown mechanism independent of G proteins. For S127L, only one study investigated
the ability to activate a non-GS pathway. Here, the authors found that it could increase pERK levels
when stimulated with NDP-α-MSH. Although it was only tested for one concentration of agonist
and no conclusion about bias could be stated, the response was significantly lower than the MC4R
WT [57]. In our hands, activation of ERK phosphorylation was also clearly impaired. The mutant
H158R was investigated for ERK phosphorylation upon NDP-α-MSH stimulation. The response to a
single concentration (1 µM) was similar to the MC4R WT [21], which is in contrast to our findings of an
increased maximal response and a clear bias towards this pathway.
3.6. Summary of the Comprehensive Functional Characterization
This is the first in vitro study ofMC4Rmutations that determined the activation of all four G protein
families in addition to ERK activation, β-arrestin2 recruitment, receptor expression and internalization.
We could demonstrate that the signaling capacity of MC4R WT depends on its endogenous ligand.
Our summarized data (Figure 7) show how each pathway was affected by the mutations. This study
was the first to investigate the activation of G12/13 signaling after cell stimulation with endogenous
ligands, although the overall activation is weak compared to other signaling pathways. So far, only
one chimera-based study hinted towards such G protein coupling [11] and the physiological role at the
MC4R still needs to be elucidated. Our study highlights that in order to understand how mutations
might limit the function of MC4R in a physiological setting, both endogenous neuropeptides need to
be investigated.
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The results of the present study show how the MC4R mutations react differently to α- and β-MSH.
Especially, the mutations V103I and H158R showed strong bias towards particular pathways, such as
PLC activation, ERK phosphorylation and RhoA activation. The ligand NDP-α-MSH was highly potent
only in GS signaling, e.g., for V103I but not in activation of PLC where it had comparable potency
to α- and β-MSH. These differences should be considered when MC4R mutations are characterized
in vitro. In addition, the data gives an ide about the antagonistic potency of AgRP, though only one
conc ntration of AgRP an one pathway has b en investigated. For further studies, we would i clude
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all signaling pathways and perform a Schild’s analysis with increasing amounts of antagonist to gain
further insight in the effect on the mutations. Evaluation of a complete set of signaling pathways offer
new opportunities for the development of treatment options. This study demonstrates that a complete
signaling profile of MC4R mutations, although necessarily done in an artificial cell system, may be
helpful to estimate the pathophysiological role of MC4R mutations. For future studies, a cell system
that is closer to the physiologic situation is urgently needed.
In conclusion, our data point out the complexity of MC4R signaling and its dependence on
specific ligands. This implies that a cautious and standardized functional characterization is necessary
to evaluate the functional impact of different MC4R mutations. This is of importance, as there is
now growing evidence that more MC4R pathways are relevant for the development of obesity than
previously expected.
4. Materials and Methods
4.1. Cell lines, Cloning and Reagents
Human embryonic kidney 293 (HEK293) cell line was purchased from ATCC, authenticated by
single nucleotide polymorphism (SNP) analysis and regularly tested for mycoplasma contamination.
Cells were cultivated in l-glutamine containing minimal essential medium (MEM, Biochrom, Berlin,
Germany) supplemented with 5% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA) and 1%
non-essential amino acids (NEA, Biochrom, Berlin, Germany) at 37 ◦C and humidified air containing
5% CO2. For cAMP measurements, reporter gene assays, total and cell surface expression (HiBiT
assay, Promega, Mannheim, Germany), 1.5 × 104 cells per well were seeded in poly-l-lysine-coated
(Biochrom, Berlin, Germany) 96-well plates and incubated for 24h. The HiBiT assays were performed
in white opaque, poly-l-lysine-coated 96-well plates (Corning, NY, USA #3917), and the other assays
in translucent well plates (Falcon, Kaiserslautern, Germany). For Bioluminescence resonance energy
transfer (BRET) assays, HEK293 cells were seeded in 6-well plates for transfection (8 × 105 cells/well)
and later reseeded in white opaque 96-well plates for measurement (2.2 × 104 cells/well).
MC4R cDNA was amplified from genomic DNA, cloned into eukaryotic expression vector pcDps
and N-terminally tagged with the hemagglutinin (5′ YPYDVPDYA 3′) epitope (HA). For β-arrestin
recruitment BRET assays, the cDNA of rARRB2 (β-arrestin2, Rattus norvegicus) was cloned into the
expression vector pFN31A (Promega, Mannheim, Germany), resulting in the N-terminal tag with
NanoLuc (NL). MC4R and cholinergic muscarinic receptor 3 (rM3R, R. norvegicus) were C-terminally
tagged with the protein tag Halotag (HT) using the pFC14A expression vector (Promega, Mannheim,
Germany) when they serve as a mock control. For MC4R, the linker between receptor and protein tag
was changed into ADPPVV using site-directed mutagenesis for improved assay performance. For total
and cell surface expression, MC4R was cloned into pBiT3.1-N (Promega, Mannheim, Germany),
resulting in an N-terminal tagged receptor with the HiBiT protein tag. The mutations V103I, S127L and
H158R were incorporated into all expression vectors using site-directed mutagenesis. Mutagenesis
primer can be found in Table S5. All plasmids were sequenced and verified with BigDye-terminator
sequencing (PerkinElmer Inc., Waltham, MA, USA) using an automatic sequencer (ABI 3710 XL;
Applied Biosystems, Foster City, CA, USA). Protein tags do not affect MC4R functionality, which was
tested via a cAMP accumulation assay (data not shown).
The compounds α-MSH, β-MSH, NDP-α-MSH, PTX and 3-Isobutyl-1-methylxanthine (IBMX)
were purchased from Sigma-Aldrich (Darmstadt, Germany), and AgRP from Phoenix Pharmaceuticals
(Karlsruhe, Germany).
4.2. Transfection
HEK293 cells were transfected 24 h after seeding. For cAMP measurements and reporter gene
assays, cells were transfected with 45 ng plasmid DNA and 0.45 µL Metafectene (Biontex, Munich,
Germany). In case of reporter gene assays, the transfection included an additional 45 ng of reporter
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DNA per well in MEM without supplements. For the HiBiT assay, transfection was performed as
described previously [67].
In order to stain the receptor with fluorophore-tagged ligand, MC4R WT and the three mutations
were transfected in HEK293 cells using Effectene® (Quiagen, Hilden, Germany) transfection reagent
according to the manufacturer’s instructions. HEK293 cells, seeded in 6-well plates (Sarstedt,
Nürnbrecht, Germany) containing 24 mm #1 glass coverslips (Fisher Scientific, Hampton, NH,
USA), were transfected with 0.4 µg DNA per well.
For BRET assays, HEK293 cells in 6 wells were transfected using 8 µL FuGene HD (Promega,
Mannheim, Germany) and 2.4 µg DNA in Opti-MEM (Gibco) 4–6 h after seeding. The BRET partners
were co-transfected with the NL:HT ratio of 1:10 (200 ng:2 µg). A total of 200 ng of pGEM-3Zf (+) was
added as carrier DNA.
4.3. Determination of Total and Cell Surface Expression via HiBiT Assay
The number of receptors expressed on the cell membrane as well as total cell expression were
determined using the NanoGlo® HiBiT detection system (Promega, Mannheim, Germany). Here,
HEK293 cells express the HiBiT-tagged receptor in low amounts and measurement was performed
according to the manufacturer’s protocol (rapid measurements protocol). In short, 48 h after transfection,
media was changed to 50 µL Opti-MEM without phenol red per well and injected with 50 µL of
either HiBiT Extracellular substrate (Promega, Mannheim, Germany) for determination of cell surface
expression or HiBiT Lytic substrate (Promega, Mannheim, Germany) for total expression using a plate
reader (Mithras LB 940, Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany). Afterwards,
the plate was shaken orbitally for 3 min at 300 cycles per minute, incubated for 10 min at room
temperature and then luminescence was measured. Cells transfected with empty pcDNA3 were used
as background control and were subtracted from the sample emissions.
4.4. Receptor Staining Using Fluorophor-Tagged Ligand
A total of 48 h after transfection and prior to imaging, cells were incubated with 100 nM
TAMRA-NDP-α-MSH for 30 min and then washed with HBSS. Cells adhering to 24 mm #1 glass
coverslips were mounted into Attofluor™ steel chambers (Thermofisher, Waltham, MA USA) and
imaged in HBSS (Thermofisher, Waltham, MA, USA) using a SP8 (Leica, Wetzlar, Germany) inverted
confocal microscope. The excitation wavelength was 561 nm (power at the sample of a few microwatts),
and emitted fluorescence from TAMRA was collected in the 580–650 nm range using a Leica HyD
Detector. The scan rate was 100 Hz, with a pixel size of the order of 50 nm.
Differential interference contrast (DIC) images were collected on a photo multiplier (PMT) placed
on top of the condenser of the microscope.
4.5. Determination of β-Arrestin2 Recruitment via NanoBRET™
The recruitment of β-arrestin2 to MC4R was determined by a novel BRET technique, the
NanoBRET™ (Promega, Mannheim, Germany), which utilizes an improved luciferase (NanoLuc, NL)
as an energy donor and a protein tag (HaloTag, HT) that can bind to the energy acceptor (HT Ligand
618). The MC4R was C-terminally tagged with HT and β-arrestin2 was N-terminally tagged with
NL. In case of a recruitment of β-arrestin2 to the receptor, which indicates the initiation of receptor
internalization, radiation-free energy transfer occurs between energy donor and energy acceptor.
A total of 16–20 h after transfection in 6-well plates, cells were detached, and cell number was
adjusted to 2.2 × 105 cells/mL in Opti-MEM without phenol red supplemented with 4% FBS. Cells
were divided into two pools, adding either the acceptor NanoBRET™ Ligand 618 (1 µL/mL cells of
0.1 mM solution) or the same amount of DMSO as background control. After reseeding 90 µL cell
suspension/well into a white 96-well plates, incubation was continued for 4–6 h.
For BRET measurements, cells were challenged with 10 µL of either α-MSH, β-MSH or
NDP-α-MSH (10 µM to 1 nM) for 5 min at 37 ◦C. For measurements, 25 µL of NanoBRET™ substrate
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was injected using a plate reader (Mithras LB 940). Donor and acceptor emission were measured at
460 nm and 610 nm, respectively, and the BRET ratio was calculated by dividing acceptor emission by
donor emission:
BRET ratio =
emissionacceptor
emissiondonor
(1)
The ratio was corrected for background bleed through by subtracting of the background ratio (no
acceptor DMSO control) and conversion to milliBRET units (mBU):
corrected BRET ratio [mBU] = (BRET ratiosample − BRET rationo acceptor control) × 1000 (2)
To calculate the difference between stimulated and basal interaction, the NET BRET was acquired
using the formula:
NET BRET = corrected BRET ratiostim − corrected BRET ratiobasal (3)
4.6. Determination of GS and Gi/o Protein Coupling via Intracellular cAMP Accumulation
GS and Gi coupling to the MC4R were determined using the AlphaScreen™ assay (Perkin Elmer
Life Science, Boston, MA, USA) performed according to the manufacturer’s protocol and described
elsewhere [68]. In brief, cells were stimulated 48h after transfection with either α-MSH, β-MSH,
NDP-α-MSH (1 µM to 0.1 nM) or co-stimulation of these three ligands was performed with 100 µM
AgRP in stimulation buffer containing IBMX for 40 min for GS coupling. Determination of Gi coupling
was investigated by pretreatment with 50 µg/mL PTX 18 h before stimulation. All stimulations were
performed at 37 ◦C and 5% CO2. Incubation was stopped by removing the compounds and lysing the
cells in lysis buffer containing IBMX for 1.5–2 h at 4 ◦C on a shaking platform.
The determination of cAMP using the AlphaScreen™ assay is a competitive immune assay based
on antibody-coupled acceptor beads that bind cAMP and streptavidin-coupled donor beads that bind
to a biotinylated cAMP probe. Excitement of the donor bead leads to the conversion of ambient oxygen
to a singlet state. In close proximity of donor and acceptor beads through binding the biotinylated
probe, the acceptor reacts with the singlet molecule and emits light. Absolute amounts of cAMP are
determined by the simultaneous measurement of a cAMP standard. The plate reader (Mithras 940 LB))
was used for the read out, at 565 nm.
4.7. Determination of NFAT, RhoA Activation and ERK Phosphorylation via Reporter Gene Assays
Activation of PLC, RhoA and ERK1/2 phosphorylation was determined using luciferase-based
reporter gene assays that utilize responsive elements in the promotor region of the gene encoding
a firefly luciferase. For PLC activation, the NFAT responsive element (NFAT-luc, pGL4.33) was
co-transfected with the receptor mutations. Similarly, co-transfections with SRF responsive element
(SRF-luc, pGL4.33, Promega, Mannheim, Germany) for RhoA activation and Serum response element
(SRE-luc, pGL3.4, Promega, Mannheim, Germany) for ERK1/2 phosphorylation were performed.
A total of 48h post transfection, cells were challenged with α-MSH, β-MSH or NDP-α-MSH (10 mM to
1 nM) in MEM without supplements for 6 h at 37 ◦C and 5% CO2. The stimulation was stopped by
discarding the media and cell lysis was induced by addition of 1× passive lysis buffer (PLB, Promega,
Mannheim, Germany) and horizontal shaking for 15 min at room temperature.
Measurement of luciferase activity provided information about the activation of the respective
second messenger by transferring 10 µL lysate into a white opaque 96-well plate. Injection of 40 µL
firefly luciferase substrate (Promega, Mannheim, Germany) and measurement of luminescence was
performed with a plate reader (Mithras LB 940).
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4.8. Mathematical Models and Statistical Analysis
Statistical analysis was performed using two-way ANOVA, followed by Dunnett’s post hoc
test in GraphPad Prism 6. Statistical significance was set at * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and
**** p ≤ 0.0001.
Concentration–response curves of each experiment were analyzed by fitting a non-linear regression
model for sigmoidal response in Graph Pad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA) to
determine potency (EC50 values). For mutations that had EC50 values outside of concentration tested,
it was set to the appropriate highest concentration tested. Signaling bias analysis was performed as
described by Kenakin (2017) [69] using the formula
∆ log(
Emax
EC50
) = log
(
Emaxtest
EC50 test
)
− log
( Emaxre f
EC50 re f
)
(4)
with test referring to the tested receptor mutation and ref being reference (MC4R WT). Emax is the
maximal response (efficiency) of the mutation, which was determined from the concentration–response
curves. Where no Emax could be determined from incomplete curves (e.g., in case of AgRP
co-stimulation), the response of the maximal concentration was substituted as has been described by
Winpenny et al. (2016) [70].
Standard error (SEM) of ∆log(Emax/EC50) was calculated using the equation:
SEM∆log =
√
(SEMtest)
2 − (SEMre f )2 (5)
where SEMtest is the standard error the tested receptor mutation and SEMref is the standard error of the
reference (MC4R WT).
Bias was calculated creating the antilog of the ∆log (Emax/EC50):
bias = 10∆ log (
Emax
EC50
) (6)
The standard error of the bias factor was determined by the equation:
SEMbias =
EC50
Emax
× 1
EC50
× SEMEmax +
Emax
EC50
× 1
Emax
× SEMEC50 (7)
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